Concurrent nimotuzumab with intensity modulated radiotherapy for locoregionally advanced aged nasopharyngeal carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035678

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Case series:Concurrent nimotuzumab with intensity modulated radiotherapy

Eligibility

Sex/Gender

All

Age

70 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Histologically proven poorly differentiated or undifferentiated carcinoma of the nasopharynx; 2. Stage III and IVA/B NPC patients; 3. aged >=70 years; 4. ECOG 0-2; 5. HB>=90g/L, ANC >=1.5x10^9/L, PLT >=80x10^9/L, AST or ALT50ml/min.

Exclusion criteria

Exclusion criteria: 1. Evidence of metastases (below the clavicle or distant) by clinical or radiographic examinations; 2. Patients with simultaneous or prior malignancy (not include basal cell carcinoma of skin); 3. Prior radiation treatment to the head and neck or any prior chemotherapy; 4. Initial surgical treatment excluding diagnostic biopsy of the primary site or neck disease.

Design outcomes

Primary

Measure	Time frame
acute adverse events;	—

Countries

China

Contacts

Public ContactHongmei Ying

Fudan University Shanghai Cancer Center

yinghm@hotmail.com+86 18317086587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026